News
9h
Zacks Investment Research on MSNUltragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIAUltragenyx Pharmaceuticals RARE announced that the FDA has issued a Complete Response Letter (CRL) for its biologics license ...
The FDA cited manufacturing issues but did not flag problems with Ultragenyx’s data package for UX111, with the biotech ...
1d
GlobalData on MSNUltragenyx receives complete response letter for UX111 BLAThe FDA's request stems from observations made during recent inspections of Ultragenyx's manufacturing facilities.
1d
Investor's Business Daily on MSNUltragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A RejectionUltragenyx Pharmaceuticals took another hit when the FDA rejected its gene therapy for patients with a rare, genetic disorder.
Novato, California Monday, July 14, 2025, 16:00 Hrs [IST] ...
While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather ...
Manufacturing issues are the latest problem for Ultragenyx Pharmaceutical Inc. to solve after last week’s disappointment in a phase III study to treat brittle bones. The U.S. FDA gave the company a ...
Olivia had been showing symptoms since she was just 7 months old — including a belly that remained swollen, hard to the touch and rounder than it should have been. Her pediatrician brushed it off as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results